AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06258317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fixation of conventional polypropylene mesh
Description: By fixation of the polyprolene mesh,patients will be divided into two groups:~Group 1 includes patients with fixation of conventional polypropylene mesh. Group 2 includes patients without fixation of the mesh.
Study NCT05710198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline eye drops 2%
Description: Eye drops containing Citicoline 2%
Study NCT05710198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eye drops containing placebo matching product
Study NCT06544252 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low glycaemic index rice-based mixed meal (GI value = 47)
Description: The mixed meal consisted of Basmati rice, chicken, and green-leafy vegetables. The energy content of the mixed meal was based on the body mass of the participant. The amount of CHO was 1.3 g.kg-1 body mass (Burke et al. 2019), and the amount of protein given was 0.5 g.kg-1 per meal (Witard, Garthe and Phillips 2019).
Study NCT06544252 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High glycaemic index rice-based mixed meal (GI value = 80)
Description: The mixed meal consisted of fragrant rice, chicken, and green-leafy vegetables.The energy content of the mixed meal was based on the body mass of the participant. The amount of CHO was 1.3 g.kg-1 body mass (Burke et al. 2019), and the amount of protein given was 0.5 g.kg-1 per meal (Witard, Garthe and Phillips 2019).
Study NCT04703257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metamizole
Description: Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days patients will be instructed to take 1000 mg paracetamol orally four times a day for four days. .
Study NCT04703257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the control group will be instructed to take a placebo tablet three times a day for four days and patients will be instructed to take 1000 mg paracetamol orally four times a day for four days.
Study NCT04520074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide, Cyclophosphamide, Carboplatin/Cisplatin
Description: CTX 400mg（250mg/m2）+VP-16 100mg (70mg/m2)d1-d3 iv 4w/6cycles , CBP(AUC=5) d1/CDDP 30mg/m2 d1-d2+CTX 600mg(400mg/m2)d1-d2 iv 8w/6cycles
Study NCT05029349 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: VOC analysis
Description: VOC analysis in exhaled air with e-noses and mass spectrometry.
Study NCT05951621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong
Description: An ancient Chinese system of postures, exercises, breathing techniques, and meditations designed to improve and enhance the body's QI.
Study NCT05951621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: guidance of nutrition and exercise
Description: Provide health promotion and guidance to participants on diet and physical exercise
Study NCT06298968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab
Description: Gemcitabine (1000mg/m²) and cisplatin (25mg/m²) on day1 and 8 every 3 weeks, with a total of 6 cycles.~Lenvatinib 8 mg once daily (QD) oral dosing, continuous use for 2 years. Adebrelimab 1200mg intravenously every 3 weeks, continuous use for 2 years.
Study NCT06240546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM6690176
Description: Administered orally
Study NCT05674383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary plexus nerve block
Description: Axillary plexus nerve block: an ultrasound-guided axillary plexus nerve block with a single injection of lidocaine 1%.
Study NCT05674383 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fracture hematoma block
Description: Fracture hematoma block: a blinded single injection into the fracture with lidocaine 1%.
Study NCT06437054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 5mg/ml
Study NCT06437054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 5mg/ml
Study NCT06437054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Hyaluronic Acid 20mg/2ml
Study NCT06437054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indocyanine green(ICG)
Description: ICG 25mg
Study NCT06437054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine green(ICG)
Description: ICG 25mg
Study NCT05896137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS0159 2mg
Description: Oral QD
Study NCT05896137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral QD
Study NCT05725044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginsengberry concentrate
Description: Ginsengberry concentrate
Study NCT05725044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05367882 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: collection of blood samples from critically ill COVID-19 patients, then serum samples are collected after centrifugation measuring IL-6, IL-10 and IP-10 by ELISA
Study NCT06426160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab 20 MG/ML [Actemra]
Description: Tocilizumab 8 mg/kg every four weeks for 24 weeks.
Study NCT06426160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: Placebo (Sodium chloride) every four weeks for 24 weeks.
Study NCT05490433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot assisted nipple sparing mastectomy(RNSM)
Description: Patients receiving RNSM and IBR are enrolled in this group. The RNSM is performed using a robotic surgical system.~The robotic surgical system includes da Vinci S, Si, X, Xi, and SP Systems. An armpit or lateral chest incision is used in this surgical procedure. A lateral chest incision is used. Posterior flow tissue collection is recommended for frozen segment biopsy during surgery. If a suspected lesion is observed on the superficial or posterior interface during surgery, a frozen section for that lesion. Biopsy is recommended. For NAC, superficial edges, and/or posterior edges in frozen intercept biopsy, If tumor invasion is identified, additional resection or postoperative radiotherapy, including skin and NAC, should be considered do. In IBR, tissue extensor insertion, prosthesis insertion, photolateral sheath, transverse abdominal rectangular sheath, or deep lower abdominal perforated vessels. The skin plate is applicable.
Study NCT05490433 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional nipple sparing mastectomy(CNSM)
Description: Patients who receive CNSM and IBR are enrolled in this group. CNSM uses a robot or endoscopic surgical system Do not travel. All kinds of skin incisions can be performed in this technique. It is recommended to collect posterior mammary gland tissue for frozen segment biopsy during surgery. If a lesion suspected of tumor invasion is observed at the edge of the surface or posterior edge during surgery, a freeze-intercept biopsy is recommended for that lesion.~If a frozen segment biopsy identifies invasion of tumors on NAC, superficial edges, and/or posterior edges, further resection or postoperative radiotherapy, including skin and NAC, is considered.~In IBR, tissue extensor insertion, prosthesis insertion, photomultiplier sheath, transverse rectangular sheath, or deep lower abdominal perforated vessels.~It includes a sheath. It is excluded if there is no IBR.
Study NCT05543031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music-Integrated Phonological Awareness training program
Description: We would like to observe the effect of the music integrated phonological awareness program on preschool cochlear implant users and to compare the phonological awareness skills of the study group with the control group before and after the online training. The program is prepared as 10 lessons. Participants were guided through online training for 5 weeks, with 20-minute sessions conducted weekly. The training was carried out via Zoom, a free virtual interview program. Each family had a computer.
Study NCT05543031 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spectral-Temporally Modulated Ripple Test (SMRT)
Description: Spectral-Temporally Modulated Ripple Test (SMRT) was used to assess the spectral discrimination ability of the study group.Speech stimuli were presented at a calibrated presentation level of 60 dB SPL in a quiet room. The child was positioned at 0° azimuth and 1-meter from the loudspeaker.
Study NCT05543031 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The Phonological Awareness Scale of Early Childhood Period (PASECP)
Description: The Phonological Awareness Scale of Early Childhood Period (PASECP) was used to measure the sound awareness and sound discrimination skills of study group pre-post training. The test has 8 sub-dimensions.
Study NCT05543031 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mismatch Negativity Test
Description: Mismatch Negativity (MMN) was used to evaluate the central auditory system.The test was used for electrophysiological recordings of the study group.The standard stimulus presented as /ba/ (%80), and the rare stimulus presented as /da/ (%20) frequency. The onset (rise) and offset (fall) times of the stimuli are 10 ms, and the plateau time is 50 ms. The interval between stimuli for both responses was 1.1 ms. A 0.1-30 Hz filter was applied. The speech stimuli intensity was 70 dB SPL. Speech stimuli were presented at a 1-meter distance from the participant, with speakers placed at an angle of 0°.
Study NCT05543031 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Early Language Development (TELD-3)
Description: Test of Early Language Development (TELD-3) measured children's receptive and expressive language skills both group for inclusion criteria.
Study NCT06003023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Monitoring
Description: A physical activity monitor (Fitbit) will be provided to participants in both arms.
Study NCT06003023 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Monitoring
Description: A physical activity monitor (Fitbit) will be provided to participants in both arms.
Study NCT06003023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Exercise Prescription
Description: Participants in both arms will receive the results of their exercise stress test, which includes information on the duration, frequency, and intensity of their physical activity.
Study NCT06003023 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tailored Exercise Prescription
Description: Participants in both arms will receive the results of their exercise stress test, which includes information on the duration, frequency, and intensity of their physical activity.
Study NCT06003023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle Education
Description: Participants in both arms will receive information on healthy living, including topics such as physical activity, sleep, stress management, and diet.
Study NCT06003023 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Lifestyle Education
Description: Participants in both arms will receive information on healthy living, including topics such as physical activity, sleep, stress management, and diet.
Study NCT06003023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Lifestyle Intervention Informed by the Theory of Planned Behavior
Description: Participants randomized to the CHD-PAL arm will receive coaching to: 1) change attitudes towards physical activity; 2) increase perceptions of other people's approval of physical activity; 3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance and will be accompanied by goal-setting.
Study NCT05542121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Therapy with Rehab CARES system
Description: 60 min sessions; 3 sessions per week; for 4 weeks; Patients uses 1 or more affordable robots to exercise the UL with adaptive games assessments as OT; standard of care PT and SLP; Subjects' motor and cognitive impairment will be used to set the game and modes. The game parameters will be adjusted according to motor and cognitive impairment of that station's user while the controller will automatically adjust assisting or resisting torques experienced. The 60 minutes will be broken up into 15-minute training intervals.
Study NCT05542121 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: 60 min sessions; 3 sessions per week; for 4 weeks of OT, PT, and SLP
Study NCT06471907 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: erector spinae plane block
Description: fascial plane injection using ultrasound
Study NCT06471907 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae plane block
Description: fascial plane injection using ultrasound
Study NCT04787289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Low standard dose of bevacizumab, combined with single agent chemotherapy (7.5mg/kg IV Q3w or 5mg/kg IV Q2w)
Study NCT04787289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Low standard dose of bevacizumab, combined with single agent chemotherapy (7.5mg/kg IV Q3w or 5mg/kg IV Q2w)
Study NCT05530980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GameDay Ready Program
Description: GameDay Ready is a 12-week, group-based behavioral weight management program in which participants will meet in-person once per week at a publicly accessible walking track. Each weekly session will be led by a trained facilitator and will include a brief educational component, participant updates on progress, group discussions about overcoming barriers, supervised competitive physical activities, and goal setting for the upcoming week. Educational content will be reinforced and social support will be provided during warmup and cool down walks. Participants will be asked to set behavioral goals toward increasing physical activity and improving dietary habits and will be provided resources to self-monitor their activity, dietary intake, and weight.
Study NCT06045325 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Orbscan II
Description: Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
Study NCT06045325 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IOL Master 700
Description: Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
Study NCT06045325 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IOL Master 500
Description: Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
Study NCT06045325 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Atlas 9000
Description: Diagnostic assessment to measure white-to-white.
Study NCT06045325 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lenstar 900
Description: Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
Study NCT06045325 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pentacam
Description: Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
Study NCT06045325 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: iTrace
Description: Diagnostic assessment to measure white-to-white and corneal thickness.
Study NCT06045325 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Argos
Description: Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
Study NCT06045325 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Manual caliper measurement
Description: Manual diagnostic assessment to measure white-to-white.
Study NCT05775328 — intervention group
Intervention type: OTHER
Intervention: Intense pulsed light
Description: Already described in the arm/group description
Study NCT06406413 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: micro-movement; electroencephalogram; MRI
Description: micro-movement; electroencephalogram; MRI
Study NCT04970693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: The different dose of furmonertinib will be given according to the generation of EGFR-TKI used as the first-line therapy. The doses and target volume of radiotherapy will be decided according to the oligoprogressive sites.
Study NCT05103098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol 400 mcg
Description: All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 400 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 400 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception
Study NCT05103098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol 800 mcg
Description: All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception
Study NCT05665322 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thermoablation with standard CT guidance
Description: Guidance with small volume breathing and high frequency. The contrast product will be venously injected in the elbow.
Study NCT05665322 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermoablation with porto-scanner guidance with Angio-CT
Description: Real time guidance, small volume and high frequency respiration. Contrast medium will be directly injected into the superior mesenteric artery (SMA) after puncture of the femoral artery at the inguinal fold and catheterization of the SMA.
Study NCT05377645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cyriax mobilization + traditional physiotherapy
Description: TENS, US, exercise
Study NCT05377645 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cyriax mobilization + traditional physiotherapy
Description: TENS, US, exercise
Study NCT05370547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 1. Chidamide monotherapy mode: Chidamide was administered for at least 6 times after leukapheresis, 10mg oral D1-4, 20mg oral D7 every 3 days to the beginning day of FC conditioning.~2. Chidamide combination mode: The combination of one or more of the following drugs in addition to chidamide is permitted: glucocorticoids, BTK inhibitors, chemotherapy, other previously used resistance drugs, etc.
Study NCT05370547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine and cyclophosphamide
Description: Patients should be received FC regimen conditioning 3 to 5 days prior to CAR-T cell infusion. The recommended regimen is intravenous fludarabine (25-30 mg/m\^2) and cyclophosphamide (250-500 mg/m\^2) daily for 3 consecutive days. The clinician may also adjust the cleansing regimen according to the patient's actual situation.
Study NCT05370547 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR-T cells
Description: A single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 100 × 10\^6 for Relma-cel or 2 × 10\^6/kg for Axi-cel. Other commercial CAR-T doses are determined by specific drug infusion instructions. The dose of experimental CAR-T was determined by the investigator. Infusion volume was calculated based on CAR-T cell density and recommended dose.
Study NCT05841056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone Hydrochloride 200 MG
Description: 200 mg daily for 4 weeks
Study NCT04189510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas
Description: The Artificial Pancreas will delivery insulin in place of Multiple Daily Injections after a kidney transplant.
Study NCT04189510 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multiple Daily Injections
Description: Multiple Daily Injections as standard of care post kidney transplant.
Study NCT05687318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DeFrame
Description: DeFrame can analyze colonoscopy medical images generated by electronic digestive endoscopy equipment to automatically identify, label and screen capture polyps in the colon.
Study NCT05643313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABLE Exoskeleton
Description: The ABLE Exoskeleton is a lower-limb overground robotic exoskeleton intended for SCI patients for rehabilitation in a clinical setting.